← Back to Analyst Consensus 
MREO Buy
Mereo BioPharma Group plc
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 19, 2026 | JP Morgan | downgrade | Neutral → Underweight | — | 55% |
| Aug 11, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Aug 11, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| May 12, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Mar 23, 2026 | JP Morgan | downgrade | Overweight → Neutral | — | 55% |
| Jan 16, 2026 | BTIG | reiterate | Buy → Buy | $1 | 52% |
| Jan 13, 2026 | Needham | maintain | Buy → Buy | $3 | 50% |
| Dec 30, 2025 | Jefferies | downgrade | Buy → Hold | $0.5 | 52% |
| Dec 29, 2025 | BTIG | maintain | Buy → Buy | $1 | 52% |
| Dec 29, 2025 | LifeSci Capital | downgrade | Outperform → Market Perform | $0 | 57% |
| Dec 22, 2025 | Needham | reiterate | Buy → Buy | $5 | 50% |
| Dec 18, 2025 | BTIG | reiterate | Buy → Buy | $6 | 52% |
| Aug 25, 2025 | JP Morgan | maintain | Overweight → Overweight | $8 | 55% |
| Jul 10, 2025 | Needham | maintain | Buy → Buy | $5 | 50% |
| May 13, 2025 | Needham | reiterate | Buy → Buy | $7 | 50% |
| Apr 9, 2025 | Needham | reiterate | Buy → Buy | $7 | 50% |
| Mar 27, 2025 | JP Morgan | initiate | — → Overweight | $7 | 55% |
| Mar 26, 2025 | Needham | reiterate | Buy → Buy | $7 | 50% |
| Mar 18, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $7 | 50% |
| Jan 13, 2025 | Needham | reiterate | Buy → Buy | $7 | 50% |
| Dec 24, 2024 | LifeSci Capital | initiate | — → Outperform | $10 | 57% |
| Dec 17, 2024 | Needham | reiterate | Buy → Buy | $7 | 50% |
| Dec 6, 2024 | Jefferies | initiate | — → Buy | $7 | 52% |
| Nov 12, 2024 | Needham | reiterate | Buy → Buy | $7 | 50% |
| Oct 1, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $7 | 50% |
| Sep 16, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $7 | 50% |
| Aug 13, 2024 | Needham | reiterate | Buy → Buy | $7 | 50% |
| Jul 22, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $7 | 50% |
| Jun 20, 2024 | Leerink Partners | maintain | Outperform → Outperform | $8 | 50% |
| Jun 13, 2024 | Baird | initiate | — → Outperform | $8 | 55% |
| Jun 12, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $7 | 50% |
| Jun 12, 2024 | Needham | maintain | Buy → Buy | $7 | 50% |
| May 16, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $7 | 50% |
| May 16, 2024 | Needham | reiterate | Buy → Buy | $6 | 50% |
| Apr 10, 2024 | Needham | reiterate | Buy → Buy | $6 | 50% |
| Mar 28, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $7 | 50% |
| Mar 28, 2024 | Needham | maintain | Buy → Buy | $6 | 50% |
| Mar 22, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $7 | 50% |
| Sep 8, 2023 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $4 | 50% |
| Sep 8, 2023 | Needham | reiterate | Buy → Buy | $5 | 50% |
| Aug 23, 2023 | Needham | reiterate | Buy → Buy | $5 | 50% |
| Jun 6, 2023 | Needham | reiterate | Buy → Buy | $5 | 50% |
| May 26, 2023 | Needham | reiterate | Buy → Buy | $5 | 50% |
| Apr 21, 2023 | Needham | reiterate | — → Buy | $5 | 50% |
| Mar 30, 2023 | Needham | reiterate | — → Buy | $5 | 50% |
| Nov 10, 2022 | SVB Leerink | maintain | — → Outperform | $4 | — |
| Aug 12, 2022 | Cantor Fitzgerald | initiate | — → Overweight | $4 | 50% |
| Jun 6, 2022 | Needham | maintain | — → Buy | $5 | 50% |
| May 5, 2021 | BTIG | initiate | — → Buy | $10 | 52% |
| Apr 5, 2021 | Needham | initiate | — → Buy | $10 | 50% |
Price Target Trend
Apr 23, 2026 Latest: $1.99 Oct 22, 2026
EPS Estimates
+1q $-0.01
Lo: $-0.03 Hi: $-0.01
6 analysts 0q $-0.01
Lo: $-0.03 Hi: $-0.01
6 analysts 0y $-0.04
Lo: $-0.13 Hi: $-0.02
6 analysts +1y $-0.02
Lo: $-0.05 Hi: $0.02
6 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days